Price T Rowe Associates Inc Ngm Biopharmaceuticals Inc Transaction History

Price T Rowe Associates Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.17 - $1.92 $916 - $1,503	783 Added 7.76%	10,869 $18,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $20,520 - $44,802	-34,200 Reduced 77.23%	10,086 $9,000
Q3 2023 Nov 14, 2023	SELL	$1.05 - $3.37 $2,810 - $9,021	-2,677 Reduced 5.7%	44,286 $48,000
Q1 2023 May 15, 2023	BUY	$3.72 - $5.4 $25,206 - $36,590	6,776 Added 16.86%	46,963 $192,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $21,285 - $80,709	6,242 Added 18.39%	40,187 $202,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $170,027 - $238,633	13,505 Added 66.07%	33,945 $445,000
Q2 2022 Aug 15, 2022	BUY	$10.58 - $17.5 $15,076 - $24,937	1,425 Added 7.49%	20,440 $262,000
Q1 2022 May 16, 2022	BUY	$13.81 - $18.6 $10,978 - $14,787	795 Added 4.36%	19,015 $290,000
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $6.33 Million - $8.07 Million	-366,496 Reduced 95.26%	18,220 $323,000
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $990,211 - $1.29 Million	-49,142 Reduced 11.33%	384,716 $8.09 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $819,188 - $1.63 Million	54,395 Added 14.33%	433,858 $8.56 Million
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $9.48 Million - $12.1 Million	379,463 New	379,463 $11 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.